NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Zenas BioPharma, Inc. (ZBIO) Stock Analysis

Zenas BioPharma, Inc. (ZBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ZBIO

$28.08

−$0.10 (−0.35%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZBIO with… →

ZBIO Key Statistics

As of Oct 21, 2026
Trading
Open
$28.47
Previous Close
$28.18
Day's Range
27.90–29.44
52-Week Range
13.50–44.60
Volume
483.89K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.88
Valuation
Market Cap
$1.83B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1,830.16
EPS (ttm)Profit attributable to each share over the last twelve months.
−9.63
Financials (FY)
Revenue (FY)
$10.00M+100.00%
Net Income (FY)
−$377.74M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.18M
1-Year Return
+7.88%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
687.43K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ZBIO closed at $28.08, +7.88% over 1 year.

Zenas BioPharma, Inc. (ZBIO) has a market capitalization of $1.83B.

In fiscal 2025, ZBIO reported revenue of $10.00M.

ZBIO Stock Return by Calendar Year

Zenas BioPharma, Inc. (ZBIO) return since Sep 2024: what $10,000 became

1 year
$10,000 $10,788
+7.88%
Since Sep 2024
$10,000 $15,471
+54.71%

If you had invested $10,000 in Zenas BioPharma, Inc. (ZBIO) at the close on September 13, 2024, the earliest close on record here, it would have been worth $15,471 at the close on October 21, 2026: +54.71% in total, +23.06% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−22.67%
2025+343.35%
2024 (partial year)−54.88%

As of October 21, 2026.

ZBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$10.00M−$377.74M−3,777.4%
2024$5.00M−$156.99M−3,139.8%
2023$50.00M−$37.12M−74.2%
2022$0.00−$119.28M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$10.00M—−$211.39M−$377.74M−3,777.4%
2024$5.00M—−$163.89M−$156.99M−3,139.8%
2023$50.00M—−$27.15M−$37.12M−74.2%
2022$0.00—−$75.20M−$119.28M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZBIO Valuation vs Biotechnology Median

Median of 608 stocks
MetricZBIOBiotechnology medianvs median
P/S ratio1,830.1613.30137.6x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Zenas BioPharma, Inc. (ZBIO) is capitalised at $1.83B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 167.

The 52-week range on file runs from $13.50 to $44.60. ZBIO last closed at $28.08 on October 21, 2026. That is −$0.10 (−0.35%) against the previous close. The latest close sits 108% above that 52-week low.

Financial Health

In fiscal 2025, Zenas BioPharma, Inc. reported revenue of $10.00M. That is +100.00% against the prior fiscal year, when revenue was $5.00M. The same year closed with a net loss of $377.74M. Earnings per share on a trailing basis come to −9.63.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $10.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1,830.16 times revenue. On price-to-sales that is 137.6 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +7.88%. The stored price history starts on September 13, 2024, and the total return since then is +54.71%. Beta against the wider market is reported at −0.88. Daily returns over the trailing 2 years annualize to a volatility of 103.57%.

Growth & Income

The record shows no dividend for ZBIO.

The record holds one complete calendar year, 2025, which returned +343.35%. 2026 is still running; the total return is −22.67% year to date.

Peer Comparison

Zenas BioPharma, Inc. (ZBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Zenas BioPharma, Inc. ZBIO $1.83B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Zenas BioPharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Visit website →